Darwin

Darwin AAQS

The The AAQS of Darwin (7V0.DE) as of Nov 1, 2026 is 2. In the previous year, The AAQS was 2.00 — a change of 0.00% (lower).

AAQS

2

YoY

0.00%

Last updated:

Darwin has a current AAQS of 2.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock Darwin in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The Darwin AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2021
2.00 EUR
Jan 1, 2022
2.00 EUR
Jan 1, 2023
2.00 EUR
Jan 1, 2024
2.00 EUR
Jan 1, 2025
2.00 EUR
The Darwin AAQS history
YEARAAQSYoY
20.00%
20.00%
20.00%
20.00%
2—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Darwin Stock analysis

What does Darwin do? Darwin AG generates revenue through the development and sale of dietary supplements and cosmetics products. The company leverages biotechnology and AI to create personalized solutions based on scientific lab analysis data. Its fully licensed laboratories offer genetic and metabolomic testing services, including lifestyle personal genomics and embryo screening during IVF to improve success rates. These services are provided to clients seeking personalized health and wellness solutions. The firm's products and services target individuals interested in personalized health, including those undergoing IVF treatments. The company's focus on genetic and metabolomic testing enables it to provide tailored recommendations for dietary supplements and cosmetics. This approach aligns with the growing demand for data-driven health and wellness products in the market. Darwin AG's business model integrates advanced biotechnology with AI to analyze genetic materials, which informs the development of its product lines. The company's fully licensed laboratories ensure compliance and quality in all testing services. Revenue streams are derived from both product sales and service-based offerings, catering to a segment of consumers prioritizing personalized health solutions. Darwin is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Darwin stock

The AAQS of Darwin is 2 in 2025.

On Eulerpool you can find the complete historical development of The AAQS Darwin since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Darwin

All Key Metrics — Darwin